On 21 December 2015, under the guidance of China Securities Regulatory Commission Shanghai Securities Bureau and Shanghai Stock Exchange, the first China (Shanghai) Listed Company Corporate Social Responsibility Summit and the press conference of Corporate Social Responsibility Blue Book of Listed Companies in Shanghai (2015), jointly organized by Xinhua News Agency Shanghai Branch, Xinhua Net, China Financial Information Center, Shanghai Listed Companies Association, Shanghai Securities News, and Research Center for Corporate Social Responsibility Chinese Academy of Social Sciences, were convened in Shanghai.

Reportedly, the Corporate Social Responsibility Blue Book of Listed Companies in Shanghai (2015), released by Research Center for Corporate Social Responsibility Chinese Academy of Social Sciences (the “Center”) for the first time, was composed based on the research and analysis of 206 listed companies registered in Shanghai conducted by a joint research group established by institutions including the Center, Xinhua News Agency Shanghai Branch, Shanghai Listed Companies Association and so on. The Blue Book disclosed the assessment results of the CSR development index of listed companies in Shanghai (2015) and the CSR reports of listed companies in Shanghai (2015), wherein Fosun Pharma occupied the first place in both assessments.

The CSR development index is a comprehensive index assessing the construction status of enterprises’ CSR system and the society/ environment information disclosure level. While interpreting the Blue Book, Mr. Zhong Hongwu, Director of the Research Center for Corporate Social Responsibility Chinese Academy of Social Sciences, expressed, “the Center has conducted research on the latest progress of the CSR work of listed companies in Shanghai from 2014 to 2015, and thereafter formulated the ‘CSR development index of listed companies in Shanghai (2015)’, so as to strengthen responsibility management of listed companies in Shanghai and accelerate the construction of society/ environment transparency.” By using the “four-in-one” theoretical model of responsibility management, market management, social responsibility and environmental responsibility, the CSR development index has referred to international social responsibility standards like ISO26000, domestic initiative documents pertaining to social responsibility published by CSRC, Shanghai and Shenzhen stock exchanges, and Fortune 500’s CSR report metrics. The CSR development index has optimized social responsibility indicator system (breakdown by industries), and gathered social responsibility information for the period from 2014 to 2015 of listed companies in Shanghai from corporate CSR reports, corporate annual reports, corporate separate reports, and corporate websites, analyzing and assessing the content of which to conclude the final score and ranking. Fosun Pharma, with a combined score of 73.5, ranks first in the assessment and is rated as a “four-star enterprise”. Meanwhile, Shyndec Pharmaceutical Company, China Unicom, Shanghai Pharmaceuticals, Bao Steel, and SAIC Group are also among the top enterprises with high scores.

Mr. Zhong also expressed that, in respect to corporate performance, more than half of the enterprises (117 enterprises) belong to the one-star level, which means they are in the phase as “bystanders”; while only 10 enterprises are graded as four-star, occupying the position as “leaders”.

The assessment result of CSR reports in the Blue Book, analyzing the overview and quality of CSR reports of listed companies in Shanghai released in 2015, has systematically evaluated from six major indicators, namely completeness, substantiality, balance, comparability, readability and innovativeness. Fosun Pharma, with a combined score of 83.8 and sub-scores in substantiality, readability, comparability and innovativeness exceeding 90, occupies the first place again. In the meantime, China Unicom, Bao Steel, Pudong Construction and Eastern Airlines also achieved high scores.

Fosun Pharma has been releasing its Corporate Social Responsibility Report annually together with its Annual Report (A-Share) since it started the practice in 2009. In 2015, Fosun Pharma’s 2014 Corporate Social Responsibility Report was released both in the A-share and H-share market, with the H-share version being published in English and Traditional Chinese. The report showed Fosun Pharma’s measures and progresses in strategic management, economic responsibility, quality of product and service, environmental protection, occupational health and safety, staff development and public welfare, and stating the Company’s strategy of sustainable development. SGS, the review institution, expressed in its statement that, the report had improved the sustainable development strategy and social responsibility system, becoming a benchmark for the pharmaceutical industry. Fosun Pharma’s corporate social responsibility reports were awarded “Annual AA+ Grade” by Rankin’s CSR Ratings for many times, ranking first in the industry. Meanwhile, Fosun Pharma has received the Golden Bee Social Responsibility Award organized by WTOGuide for three times.

Being a leading pharmaceutical and healthcare industry group in China, Fosun Pharma, remaining on its mission to promote health and well-being and adhering to the principal of sustainable development, has actively assumed corporate social responsibility from aspects including strategy management, economic development, products and services, and environmental health and safety, striving to create a more harmonious industry ecosphere. In respect to public welfare activities, since 1998, Fosun Pharma has attended and organized a number of activities in education & research, environmental protection, medicines & healthcare, social demand and culture with projects implemented across China and other countries and regions. Currently, the Company has built a complete public welfare system - “Future Star” public welfare program. By investing in education, supporting scientific researches, engaging in the community healthcare, treating diseased orphans, alleviating poverty by donations, and providing disaster assistances, Fosun Pharma undertakes its social responsibilities and do its part in benefiting the society.

Mr. Chen Qiyu, Chairman of Fosun Pharma, expressed that, self-discipline of an enterprise leads to a more harmonious ecosphere. We are striving for a higher and tighter sustainability standard, and setting ourselves as an example for purifying the overall market environment of medicine industry, which will promote the development of ecology regarding the entire industry in a healthier and more sustainable way.